Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report issued on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Down 0.5 %

Shares of TTNP opened at $3.62 on Wednesday. Titan Pharmaceuticals has a one year low of $3.51 and a one year high of $14.80. The business has a fifty day moving average of $4.22 and a 200 day moving average of $5.35.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.